Hodgkin Lymphoma Research Review, Issue 6

In this issue:

ACCRU assesses BV plus nivolumab as front-line therapy in older patients with HL
Front-line BV monotherapy elicits suboptimal responses in elderly patients
Cost-effectiveness of BV in advanced HL
No difference between second-line chemotherapy versus ASCT for early-stage, favourable HL
Consolidation radiotherapy in advanced HL with large nodal mass in complete metabolic response after ABVD
Induction pembrolizumab followed by AVD elicits high complete response rates in newly diagnosed cHL
Significantly increased risks of non-lymphoma related mortality in chemotherapy-treated patients with cHL
Potential impact of consolidation radiation therapy in patients with residual disease following chemotherapy
Daily low-dose continuous lenalidomide in heavily pre-treated relapsed/refractory disease
HL arising in patients with chronic lymphocytic leukaemia

Please login below to download this issue (PDF)

Subscribe